You are here: Industry Insights > asthma drug

News List

GSK’s asthma drug Nucala meets co-primary endpoints in SYNAPSE trial pharmaceutical-business-review
April 08, 2020
GlaxoSmithKline (GSK) said that its asthma drug Nucala (mepolizumab) has succeeded in the phase 3 SYNAPSE trial in patients with nasal polyps associated with chronic rhinosinusitis (CRSwNP).
Pulmatrix and Cipla collaborate to develop asthma drug pharmaceutical-technology
April 18, 2019
Pulmatrix and Cipla Technologies have signed a definitive agreement to jointly develop and commercialise Pulmazole to treat allergic bronchopulmonary aspergillosis (ABPA) in asthma patients.
NICE broadens approval for AstraZeneca’s severe asthma drug pharmaphorum
January 07, 2019
AstraZeneca’s Fasenra (benralizumab) has seen its fortunes reverse after NICE approved the drug for severe eosinophilic asthma – broadening its recommendations for......
Vectura takes £40 million hit as asthma drug fails trial pharmaphorum
November 28, 2018
Vectura has abandoned a late-stage drug in severe uncontrolled asthma after it failed a phase 3 trial, resulting in a decline in its already-depressed share price.
GSK’s asthma biologic hits quality of life goal pharmatimes
March 08, 2017
GlaxoSmithKline has presented new data showing that its asthma drug Nucala “significantly improves” quality of life and lung function in patients with ...